Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Arrowhead Publishers | Monoclonal Antibodies 2007

Monoclonal Antibodies 2007

In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. This share increased substantially since 2001, when it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies have been posting the fastest growth within the protein therapeutics market. According to Arrowhead Publishers’ report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006This growth will continue in the coming years, boosted by a number of new MAbs on the market, new indications for successful medications, and their ability to treat conditions and diseases for which there is great unmet need.

Monoclonal Antibody Therapies 2007 provides an analytically-based overview of the growing market for therapeutic monoclonal antibodies, which represent the largest segment of protein-based therapeutics. An increasing number of biotech companies are investing in the MAbs field, mostly in collaboration with major pharmaceutical companies, to take advantage of this dynamic and growing field.

This report assesses the overall monoclonal antibody market, as part of the wider protein therapeutics industry. Factors influencing their historical and future performance - including manufacturing problems and the impact of future generic competition - are assessed to provide a balanced overview of the market and key products by major therapeutic categories. Finally, the report forecasts likely revenue performance of the most successful products in the next five years, identifying key areas of growth.

Key Features of this report:

Thorough market analysis of global monoclonal antibody sales, segmented by product, company, and geographic region

Financial forecasts for key MAbs on the market as well as promising new MAbs entering the market

Analysis of MAb manufacturing issues and their effect on the financial potential of the therapeutic MAb market

Profiles of key companies involved in the development and marketing of therapeutic MAbs

A review of important happenings in R&D and an evaluation of the upcoming crop of new MAbs

Publication Date: January 7, 2007

Pages: 158 Format PDF
Table of Contents

Price

Single User PDF $2250.00

Site Licence PDF $4499.00

Corporate Wide Licence PDF $5499.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions